CN103108548A - 使用环酰胺衍生物治疗σ受体介导的病症的方法 - Google Patents
使用环酰胺衍生物治疗σ受体介导的病症的方法 Download PDFInfo
- Publication number
- CN103108548A CN103108548A CN2011800450188A CN201180045018A CN103108548A CN 103108548 A CN103108548 A CN 103108548A CN 2011800450188 A CN2011800450188 A CN 2011800450188A CN 201180045018 A CN201180045018 A CN 201180045018A CN 103108548 A CN103108548 A CN 103108548A
- Authority
- CN
- China
- Prior art keywords
- alkyl
- compound
- mean
- treatment
- group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 0 CN(C(CC(*S)C1)C2*C2)C1I Chemical compound CN(C(CC(*S)C1)C2*C2)C1I 0.000 description 2
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N43/00—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds
- A01N43/34—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with one nitrogen atom as the only ring hetero atom
- A01N43/40—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with one nitrogen atom as the only ring hetero atom six-membered rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/02—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Psychiatry (AREA)
- Addiction (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Anesthesiology (AREA)
- Psychology (AREA)
- Child & Adolescent Psychology (AREA)
- Diabetes (AREA)
- Agronomy & Crop Science (AREA)
- Pest Control & Pesticides (AREA)
- Plant Pathology (AREA)
- Dentistry (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Environmental Sciences (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
1. 评估CYR-101在治疗一个月(28天+/-2天)后相对安慰剂对总体PANSS分数和子分数的功效 |
2. 测试在治疗三个月(84天+/-2天)后由PANSS总分数和子分数评价的CYR-101的给药剂量是否会显著地呈现出更大的功效 |
3. 评估在治疗一个和三个月后由CGI-S评价的CYR-101相对安慰剂的功效 |
4. 评估在治疗一个和三个月后由药物态度量表-10(Drug Attitude Inventory-10)(DAI-10)评价的CYR-101相对安慰剂的患者主观功效 |
5. 评估在治疗三个月后由匹兹堡睡眠质量指数(PSQI)评价的主观睡眠质量 |
6. 探索在治疗一个和三个月后由BACS(简明精神分裂症认知评估)量表检测的CYR-101与安慰剂相比对认知功能的功效 |
7. 评估在治疗一个月后由蒙哥马利-艾森贝格抑郁评定量表(MADRS)的总分数测量的CYR-101相对安慰剂在抑郁症状中的功效 |
8. 评估在治疗一个月后由汉米尔顿焦虑量表(HAMA)的总分数测量的CYR-101相对安慰剂在焦虑中的功效 |
9. 与安慰剂相比,评估CYR-101的心血管安全性(特别是由QT/QTc间期测量值评价的心室复极化) |
10. 与安慰剂相比,评估CYR-101的总体安全性和耐受性 |
11. 测定CYR-101在精神分裂症患者中的药代动力学 |
Claims (16)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201611063838.0A CN107007603A (zh) | 2010-07-20 | 2011-07-20 | 使用环酰胺衍生物治疗σ受体介导的病症的方法 |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US36608010P | 2010-07-20 | 2010-07-20 | |
US61/366080 | 2010-07-20 | ||
PCT/US2011/044698 WO2012012543A1 (en) | 2010-07-20 | 2011-07-20 | Methods of use cyclic amide derivatives to treat sigma receptor-mediated disorders |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201611063838.0A Division CN107007603A (zh) | 2010-07-20 | 2011-07-20 | 使用环酰胺衍生物治疗σ受体介导的病症的方法 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN103108548A true CN103108548A (zh) | 2013-05-15 |
Family
ID=45497167
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN2011800450188A Pending CN103108548A (zh) | 2010-07-20 | 2011-07-20 | 使用环酰胺衍生物治疗σ受体介导的病症的方法 |
CN201611063838.0A Pending CN107007603A (zh) | 2010-07-20 | 2011-07-20 | 使用环酰胺衍生物治疗σ受体介导的病症的方法 |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201611063838.0A Pending CN107007603A (zh) | 2010-07-20 | 2011-07-20 | 使用环酰胺衍生物治疗σ受体介导的病症的方法 |
Country Status (15)
Country | Link |
---|---|
US (3) | US20130274290A1 (zh) |
EP (2) | EP4070794A3 (zh) |
JP (3) | JP2013531073A (zh) |
KR (1) | KR101867634B1 (zh) |
CN (2) | CN103108548A (zh) |
BR (1) | BR112013001302A2 (zh) |
CA (2) | CA2805904C (zh) |
DK (1) | DK2595485T3 (zh) |
ES (1) | ES2914120T3 (zh) |
HU (1) | HUE058736T2 (zh) |
PL (1) | PL2595485T3 (zh) |
PT (1) | PT2595485T (zh) |
RU (2) | RU2613201C2 (zh) |
TW (1) | TWI520949B (zh) |
WO (1) | WO2012012543A1 (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN107567444A (zh) * | 2014-12-02 | 2018-01-09 | 田边三菱制药株式会社 | 用于治疗精神分裂症的包含2‑((1‑(2‑(4‑氟苯基)‑2‑氧代乙基)哌啶‑4‑基)甲基)异吲哚啉‑1‑酮的组合物 |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8937900B2 (en) | 2010-07-20 | 2015-01-20 | Qualcomm Incorporated | Enhancing pilot channel transmission in TD-SCDMA multicarrier systems using secondary carrier frequencies |
WO2015191554A1 (en) * | 2014-06-09 | 2015-12-17 | Intra-Cellular Therapies, Inc. | Compounds and methods of use to treat schizophrenia |
SG10202011470UA (en) * | 2016-05-25 | 2021-01-28 | Mitsubishi Tanabe Pharma Corp | Compositions and methods for treating negative symptoms in non-schizophrenic patients |
JP2020525436A (ja) | 2017-06-21 | 2020-08-27 | ミネルバ・ニューロサイエンシズ・インコーポレイテッド | 胃耐性制御放出経口剤形 |
EP3840835A1 (en) * | 2018-08-21 | 2021-06-30 | Minerva Neurosciences, Inc. | Use of roluperidone to treat negative symptoms and disorders, increase neuroplasticity, and promote neuroprotection |
EP4153209A1 (en) | 2020-05-20 | 2023-03-29 | The Board of Trustees of the University of Illinois | Method for treating lysosomal storage diseases with histatin peptides |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1991006297A1 (en) * | 1989-10-27 | 1991-05-16 | The Du Pont Merck Pharmaceutical Company | (n-phthalimidoalkyl) piperidines |
JPH07506107A (ja) * | 1992-04-23 | 1995-07-06 | メレルダウファーマスーティカルズ インコーポレイテッド | セロトニン5ht↓2拮抗剤としての4‐イミドメチル‐1‐[2’フェニル‐2’オキソエチル‐]ピペリジン類,それらの製法及び治療用途 |
CN1426405A (zh) * | 2000-02-29 | 2003-06-25 | 三菱制药株式会社 | 新型环状酰胺衍生物 |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IE903857A1 (en) * | 1989-10-27 | 1991-05-08 | Du Pont Merck Pharma | (N-Phthalimidoalkyl)Piperidines |
TW200817400A (en) * | 2006-05-30 | 2008-04-16 | Elbion Ag | Pyrido [3,2-e] pyrazines, their use as inhibitors of phosphodiesterase 10, and processes for preparing them |
-
2011
- 2011-07-20 HU HUE11810350A patent/HUE058736T2/hu unknown
- 2011-07-20 BR BR112013001302A patent/BR112013001302A2/pt not_active Application Discontinuation
- 2011-07-20 EP EP22162273.1A patent/EP4070794A3/en active Pending
- 2011-07-20 ES ES11810350T patent/ES2914120T3/es active Active
- 2011-07-20 PT PT118103506T patent/PT2595485T/pt unknown
- 2011-07-20 DK DK11810350.6T patent/DK2595485T3/da active
- 2011-07-20 CA CA2805904A patent/CA2805904C/en active Active
- 2011-07-20 WO PCT/US2011/044698 patent/WO2012012543A1/en active Application Filing
- 2011-07-20 RU RU2013107378A patent/RU2613201C2/ru active
- 2011-07-20 CA CA3154027A patent/CA3154027A1/en active Pending
- 2011-07-20 RU RU2017105262A patent/RU2746871C2/ru active
- 2011-07-20 CN CN2011800450188A patent/CN103108548A/zh active Pending
- 2011-07-20 JP JP2013520841A patent/JP2013531073A/ja active Pending
- 2011-07-20 TW TW100125662A patent/TWI520949B/zh active
- 2011-07-20 PL PL11810350T patent/PL2595485T3/pl unknown
- 2011-07-20 KR KR1020137004218A patent/KR101867634B1/ko active IP Right Grant
- 2011-07-20 EP EP11810350.6A patent/EP2595485B1/en active Active
- 2011-07-20 CN CN201611063838.0A patent/CN107007603A/zh active Pending
- 2011-07-20 US US13/810,775 patent/US20130274290A1/en not_active Abandoned
-
2016
- 2016-05-24 US US15/163,385 patent/US20160354357A1/en not_active Abandoned
- 2016-07-07 JP JP2016135208A patent/JP2016199578A/ja active Pending
-
2017
- 2017-11-22 JP JP2017225061A patent/JP6419294B2/ja active Active
-
2020
- 2020-06-29 US US16/914,862 patent/US20210106573A1/en active Pending
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1991006297A1 (en) * | 1989-10-27 | 1991-05-16 | The Du Pont Merck Pharmaceutical Company | (n-phthalimidoalkyl) piperidines |
JPH07506107A (ja) * | 1992-04-23 | 1995-07-06 | メレルダウファーマスーティカルズ インコーポレイテッド | セロトニン5ht↓2拮抗剤としての4‐イミドメチル‐1‐[2’フェニル‐2’オキソエチル‐]ピペリジン類,それらの製法及び治療用途 |
CN1426405A (zh) * | 2000-02-29 | 2003-06-25 | 三菱制药株式会社 | 新型环状酰胺衍生物 |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN107567444A (zh) * | 2014-12-02 | 2018-01-09 | 田边三菱制药株式会社 | 用于治疗精神分裂症的包含2‑((1‑(2‑(4‑氟苯基)‑2‑氧代乙基)哌啶‑4‑基)甲基)异吲哚啉‑1‑酮的组合物 |
Also Published As
Publication number | Publication date |
---|---|
RU2017105262A3 (zh) | 2019-01-18 |
WO2012012543A1 (en) | 2012-01-26 |
EP2595485A1 (en) | 2013-05-29 |
US20210106573A1 (en) | 2021-04-15 |
CA2805904C (en) | 2022-06-21 |
CA2805904A1 (en) | 2012-01-26 |
RU2013107378A (ru) | 2014-08-27 |
PL2595485T3 (pl) | 2022-06-20 |
EP2595485A4 (en) | 2014-04-23 |
JP2018065829A (ja) | 2018-04-26 |
US20160354357A1 (en) | 2016-12-08 |
PT2595485T (pt) | 2022-05-30 |
JP2016199578A (ja) | 2016-12-01 |
HUE058736T2 (hu) | 2022-09-28 |
US20130274290A1 (en) | 2013-10-17 |
TW201211022A (en) | 2012-03-16 |
CA3154027A1 (en) | 2012-01-26 |
CN107007603A (zh) | 2017-08-04 |
JP2013531073A (ja) | 2013-08-01 |
TWI520949B (zh) | 2016-02-11 |
DK2595485T3 (da) | 2022-05-30 |
RU2613201C2 (ru) | 2017-03-15 |
EP4070794A2 (en) | 2022-10-12 |
EP4070794A3 (en) | 2023-01-18 |
RU2746871C2 (ru) | 2021-04-21 |
JP6419294B2 (ja) | 2018-11-07 |
BR112013001302A2 (pt) | 2017-07-04 |
KR20130129906A (ko) | 2013-11-29 |
ES2914120T3 (es) | 2022-06-07 |
EP2595485B1 (en) | 2022-03-16 |
RU2017105262A (ru) | 2019-01-18 |
KR101867634B1 (ko) | 2018-06-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Miyamoto et al. | Antipsychotic drugs | |
CN103108548A (zh) | 使用环酰胺衍生物治疗σ受体介导的病症的方法 | |
JP2020045345A (ja) | ブレクスピプラゾール又はその塩を含有する神経変性疾患に伴う周辺症状又は精神疾患に伴う衝動性症状の予防及び/又は治療剤 | |
US9732059B2 (en) | Methods of use of cyclic amide derivatives to treat schizophrenia | |
MX2007011436A (es) | Ligando del receptor nicotinico neuronal 7 y composiciones antipsicoticas. | |
US20220274951A1 (en) | Methods of use of cyclic amide derivatives to treat schizophrenia | |
IL262921A (en) | Combination of pure 5-ht6 receptor antagonists with acetylcholinesterase inhibitors | |
US20090012101A1 (en) | Mucarinic Agonists and Methods of Use Thereof | |
CN109640975B (zh) | 组胺-3受体反向激动剂与乙酰胆碱酯酶抑制剂的组合 | |
DK2437744T3 (en) | The modulation of the KCNQ potassium channel activity for the treatment of psychiatric disorders and symptoms thereof | |
WO2020094592A1 (en) | Compounds for treating negative symptoms and cognitive impairments | |
JP2005060286A (ja) | 統合失調症の治療 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C41 | Transfer of patent application or patent right or utility model | ||
CB02 | Change of applicant information |
Address after: New jersey, USA Applicant after: MINERVA NEUROSCIENCES, Inc. Address before: New jersey, USA Applicant before: CYRENAIC PHARMACEUTICALS, Inc. |
|
COR | Change of bibliographic data | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20161228 Address after: Osaka City, Osaka of Japan Applicant after: MITSUBISHI TANABE PHARMA Corp. Address before: New jersey, USA Applicant before: MINERVA NEUROSCIENCES, Inc. |
|
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20130515 |
|
RJ01 | Rejection of invention patent application after publication |